title: Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.
abstract: Adaptive chemoresistance and consequent tumor recurrence present major obstacles to the improvement of the prognosis and quality-of-life of patients with advanced-stage ovarian cancer. In this issue of Cancer Cell, Yu and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by modulating the stability of microtubules.
authors.affiliation: Center for Cancer Research, The Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.affiliation: Center for Cancer Research, The Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: mbirrer@partners.org.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Birrer
mesh_terms: D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors*; D008870:Microtubules / Q000187:drug effects*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010078:Oxazines / Q000008:administration & dosage*; D017239:Paclitaxel / Q000008:administration & dosage*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000008:administration & dosage*
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D010078:Oxazines; D011725:Pyridines; D011505:Protein-Tyrosine Kinases; D017239:Paclitaxel